Nektar Therapeutics (NKTR)
Stock Price:
$17.17 USD
0.30 (1.78%)
Updated Oct 20, 2020 4:00 PM EDT - Market closed
After-hours: $16.94 -0.23 (-1.34%) Oct 20, 5:07 PM
Key Info
| Market Cap |
3.07B |
| Revenue (ttm) |
162.50M |
| Net Income (ttm) |
-430.90M |
| Shares Out |
178.90M |
| EPS (ttm) |
-2.43 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 20, 2020 |
| Last Price |
$17.17 |
| Previous Close |
$16.87 |
| Change ($) |
0.30 |
| Change (%) |
1.78% |
| Day's Open |
17.05 |
| Day's Range |
16.83 - 17.37 |
| Day's Volume |
730,802 |
| 52-Week Range |
13.63 - 28.60 |
More Stats
| Market Cap |
3.07B |
| Enterprise Value |
2.19B |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
178.90M |
| Float |
176.59M |
| EPS (basic) |
-2.44 |
| EPS (diluted) |
-2.43 |
| FCF / Share |
-2.07 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
25.47M |
| Short Ratio |
21.82 |
| Short % of Float |
14.42% |
| Beta |
1.80 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
18.90 |
| PB Ratio |
2.52 |
| Revenue |
162.50M |
| Operating Income |
-419.72M |
| Net Income |
-430.90M |
| Free Cash Flow |
-368.43M |
| Net Cash |
881.63M |
| Net Cash / Share |
4.93 |
| Gross Margin |
57.38% |
| Operating Margin |
-258.29% |
| Profit Margin |
-265.20% |
| FCF Margin |
-226.73% |
| ROA |
-12.67% |
| ROE |
-30.53% |
| ROIC |
-22.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (16)
| Buy |
9 |
| Overweight |
1 |
| Hold |
6 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$31.36*
(82.64% upside)
Low
17.0
Current: $17.17
High
80.0
Target: 31.36
*Average 12-month price target from 14 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 115 | 1,193 | 308 | 165 | 231 | 201 | 149 | 81.19 | 71.48 | 159 |
| Revenue Growth | -90.4% | 287.81% | 86% | -28.32% | 14.99% | 34.77% | 83.42% | 13.59% | -55.06% | - |
| Gross Profit | 93.24 | 1,169 | 277 | 135 | 197 | 172 | 110 | 50.76 | 49.59 | 133 |
| Operating Income | -440 | 688 | -59.64 | -113 | -29.37 | -16.49 | -120 | -141 | -124 | -28.26 |
| Net Income | -441 | 681 | -96.69 | -154 | -81.18 | -53.92 | -162 | -172 | -134 | -37.94 |
| Shares Outstanding | 175 | 170 | 156 | 140 | 132 | 127 | 116 | 115 | 113 | 94.08 |
| Earnings Per Share | -2.52 | 3.78 | -0.62 | -1.10 | -0.61 | -0.42 | -1.40 | -1.50 | -1.19 | -0.40 |
| Operating Cash Flow | -329 | 718 | -80.41 | -117 | -73.08 | -142 | -38.53 | -130 | -114 | -55.87 |
| Capital Expenditures | -26.29 | -11.61 | -9.68 | -6.39 | -11.20 | -9.98 | -4.09 | -10.58 | -9.72 | -31.46 |
| Free Cash Flow | -355 | 707 | -90.09 | -123 | -84.28 | -152 | -42.62 | -140 | -123 | -87.33 |
| Cash & Equivalents | 1,325 | 1,335 | 296 | 389 | 309 | 263 | 262 | 302 | 241 | 316 |
| Total Debt | 408 | 247 | 245 | 243 | 248 | 134 | 137 | 137 | 230 | 232 |
| Net Cash / Debt | 917 | 1,088 | 50.93 | 146 | 61.42 | 129 | 125 | 166 | 11.63 | 83.96 |
| Assets | 1,977 | 2,150 | 509 | 569 | 499 | 442 | 435 | 498 | 607 | 521 |
| Liabilities | 572 | 433 | 421 | 481 | 492 | 405 | 524 | 451 | 409 | 431 |
| Book Value | 1,405 | 1,718 | 87.83 | 88.13 | 6.43 | 36.33 | -89.90 | 47.02 | 198 | 90.66 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Nektar Therapeutics |
| Country |
United States |
| Employees |
723 |
| CEO |
Howard W. Robin |
Stock Information
| Ticker Symbol |
NKTR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: NKTR |
| IPO Date |
May 3, 1994 |
Description
Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic drug, which is in Phase III clinical trial for chronic low back pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I is designed to provide rapid activation and proliferation of cancer-killing CD8+ effector T cells and NK cells. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for oncology; and NKTR-255, which is in phase I for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.